Healthcare dedicated Contract Business Development Organization
SCIENTEX is an advisory & transition management company dedicated to biotech and pharma covering mainly financing and business development matters. SCIENTEX is acting as an executive sherpa for C-level managers, in order to allow its clients to enjoy its broad field of expertise from science to the stock exchange (+100 deals to date including IPOs & Investor Relations) & our network (+39 000 biopharma & medtech dealmakers in our contact database). Complementary, thanks to in-house marketing tools (BIOTECHNEWS) and huge healthcare intelligence databases. SCIENTEX is able to support all your corporate activities. SCIENTEX's associates are as well structured to be able to work 60% more than the average working time in Europe. Thanks to our low cost fees, SCIENTEX will allow its clients to reduce their labor costs compared to FTE. SCIENTEX is supporting up to 2 clients max per associate in order to guarantee its full intensive, full time , dedicated and home office based support.
10 years as private equity investor & 10 years as corporate developer, both focused on healthcare
Tim, pharma PhD + MS finance + MS management, founded SCIENTEX in 2006 : After a first R&D experience on radiopharmaceuticals at AREVA R&D (CEA) in 1993, Tim worked as a R&D pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabetes mellitus & CNS; moved in 1999 to the private equity industry (CDC enterprises & Sofimac Partners) investing in 17 healthcare private companies (6 were acquired by industrials & 5 IPOs) from his 600 deal flow proactively sourced. In 2006, Tim founded SCIENTEX in order to act as a transition manager in business & corporate development, M&A (both buy & sell side) for healthcare SMEs, while he was advising wealthy individuals on VIX trading & working with primary & secondary private equity funds.
After +26 missions, Tim joined CROSSJECT in 2012 during its restart in order to transform its medtech business model presenting a 2M€ valuation into an Euronext listed specialty pharma (IPO in feb 14 valued 65M€). Tim, acting as CBO & member of the executive board, negotiated a 472M$ ww licensing deal on ZENEO epinephrin; while he was leading & driving the $6M refinancing closed in june 2013 while managing M&A opportunities. Tim initiated & engaged the IPO process, successfully oversubscribed 4,4 x in feb 2014 & negotiated 2 out-licensing deals for ZENEO MTX covering China valuated 360M€ including 25% royalties & covering indian regions including royalties between 20% to 40%. Globally, Tim has been involved in +100 corporate & business transactions, on sell & buy side, including 5 IPOs, 9 M&A, 8 out-licensing deals, 29 commercial deals, 28 venture deals with a worldwide coverage. To date, Tim has been board member for 26 companies.
Berenice, PharmD + MS medtech, is combining 9 years of experience in retail pharmacies and 8 years in marketing & sales for European life sciences SMEs. She is developing SCIENTEX's offer in business development towards european SMEs in order to cover deeply the 5EU market, while Tim focuses on international operations. Berenice is also updating SCIENTEX's contact database (+39000 contacts in pharma/biotech dealmakers including all participants from major business events like JPM, BIO, BioEurope, DCAT, €PLX...) and SCIENTEX's intelligence databases (+21 000 market studies updated weekly from well known intelligence providers and investment banks). Berenice also screened all 907 injectables drugs for Crossject in order to find all injectables compatible to Crossject's device. She supported Tim in the M&A missions for POI by screening 570 biotech in Europe, built the target list for the marketing mission for DiscoverX Corp, an US biotech company, and as well for Elicityl, a glycobiology company. She is currently driving the commercial development in France, Switzerland and Belgium for KYMOS, a spanish CRO since 2014.